Dataset from A Controlled, Randomized, Two-arm, Open-label, Assessor-blinded, Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment

Study HGT-HIT-094 is a multicenter study designed to determine the effect on clinical parameters of neurodevelopmental status of monthly IT administration of idursulfase-IT 10 mg for 12 months in pediatric patients with Hunter syndrome and cognitive impairment who have previously received and tolerated a minimum of 4 months of therapy with Elaprase.

HGT-HIT-094研究是一项多中心临床研究，旨在评估每月鞘内注射（intrathecal, IT）给予10mg idursulfase-IT、持续治疗12个月，对既往已接受且耐受至少4个月艾而赞（Elaprase）治疗的伴认知障碍的亨特综合征（Hunter syndrome）儿科患者的神经发育状态相关临床参数的影响。